BioNTech SE (WBO:BNTX) Issuance of Debt : €0 Mil (TTM As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is BioNTech SE Issuance of Debt?

BioNTech SE's Issuance of Debt for the three months ended in Dec. 2023 was €0 Mil.

BioNTech SE's Issuance of Debt for the trailing twelve months (TTM) ended in Dec. 2023 was €0 Mil.

BioNTech SE Issuance of Debt Historical Data

The historical data trend for BioNTech SE's Issuance of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioNTech SE Issuance of Debt Chart

BioNTech SE Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Issuance of Debt

Get a 7-Day Free Trial

11.00

156.00

0.80

0.30

BioNTech SE Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Issuance of Debt	Get a 7-Day Free Trial															0.20	-	-	0.10	0.20

BioNTech SE Issuance of Debt Calculation

Issuance of Debt represents all the cash inflow from debt, including both long-term debt and short-term debt.

Issuance of Debt for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €0 Mil.

BioNTech SE Issuance of Debt Related Terms

Thank you for viewing the detailed overview of BioNTech SE's Issuance of Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

BioNTech SE (WBO:BNTX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioNTech SE (WBO:BNTX) » Definitions » Issuance of Debt

Comparable Companies

Traded in Other Exchanges

BNTX:USA BNTX:Mexico 0A3M:UK 22UA:Germany B1NT34:Brazil

Address

An der Goldgrube 12, Mainz, RP, DEU, D-55131

Website

https://www.biontech.de

BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and small-molecule immunomodulators. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. COVID-19 vaccine Comirnaty is its first commercialized product.